Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Kimberley McGrailBiomedical Research in Melanoma-Animal Models and Cancer Laboratory-Vall d´Hebron Research Institute VHIR-Vall d'Hebron Hospital-UAB, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7227-7306
Paula Granado-MartínezBiomedical Research in Melanoma-Animal Models and Cancer Laboratory-Vall d´Hebron Research Institute VHIR-Vall d'Hebron Hospital-UAB, Barcelona, Spain.
Roberto OrsenigoBiomedical Research in Melanoma-Animal Models and Cancer Laboratory-Vall d´Hebron Research Institute VHIR-Vall d'Hebron Hospital-UAB, Barcelona, Spain.
Ginevra CaratùSingle Cell Genomics Group at the Spanish National Centre for Genomic Analysis (CNAG), Barcelona, Spain.
Juan A RecioBiomedical Research in Melanoma-Animal Models and Cancer Laboratory-Vall d´Hebron Research Institute VHIR-Vall d'Hebron Hospital-UAB, Barcelona, Spain. juan.recio@vhir.org.ORCID http://orcid.org/0000-0002-7320-3832
Funding
Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) GCB15152978SOENGovernment of Catalonia | Departament de Salut, Generalitat de Catalunya 2021-SGR00653"la Caixa" Foundation (Caixa Foundation) Inphinit FellowshipMinistry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) AC16/00019Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI17/00043Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI20/0384Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI23/00428
6 · The paper itself
Abstract
The mechanisms behind UVB-initiated, neonatal-specific melanoma linked to BRAF
Indexed as
MelanocytesMelanomaProtein Serine-Threonine KinasesProto-Oncogene Proteins B-rafSkin NeoplasmsUltraviolet RaysAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsAnimals, NewbornCellular ReprogrammingGene Expression Regulation, NeoplasticHumansMiceMutationAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesBRAF protein, humanBraf protein, mouseProtein Serine-Threonine KinasesProto-Oncogene Proteins B-rafStk11 protein, mouse
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAF · full record | OpenQuestion